Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52–92 data from a randomized, double-blind, phase 3 trial

BACKGROUND/OBJECTIVE: REFLECTIONS B538–02 is a randomized, double-blind comparative study of the adalimumab (ADL) biosimilar PF-06410293, (ADL-PF), and reference ADL sourced from the European Union (ADL-EU) in patients with active RA. Therapeutic equivalence was demonstrated based on ACR20 responses...

Descripción completa

Detalles Bibliográficos
Autores principales: Fleischmann, Roy M., Alvarez, Daniel F., Bock, Amy E., Cronenberger, Carol, Vranic, Ivana, Zhang, Wuyan, Alten, Rieke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8464121/
https://www.ncbi.nlm.nih.gov/pubmed/34563243
http://dx.doi.org/10.1186/s13075-021-02626-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8464121/
https://www.ncbi.nlm.nih.gov/pubmed/34563243
http://dx.doi.org/10.1186/s13075-021-02626-4

Ejemplares similares